GenVecs TNFerade wins regulatory incentives Nov 5, 2009
GenVecs TNFerade wins regulatory incentives - Washington Business Journal ... GenVecs TNFerade wins regulatory incentives ... "Orphan drug designation is a critical step for the development of TNFerade, said GenVec CEO Dr. Paul Fischer. The designation will strengthen the TNFerade program at GenVec by offering potential clinical development and commercialization benefits," Fischer said. (Washington Business Journal, DC)
GenVec wins $2.3M for HIV vaccine work Sep 25, 2009
GenVec secures federal funds for HIV vaccine - Baltimore Business Journal ... GenVec secures federal funds for HIV vaccine ... The National Institute of Allergy and Infectious Disease, an agency within the National Institutes of Health, has decided to execute its third option year on a five-year contract wherein its Vaccine Research Center is using GenVec s manufacturing and purification processes for its own clinical development of an HIV vaccine in its Frederick plant. (Baltimore Business Journal, MD)
Cel-Sci , Novavax to raise $30M Sep 22, 2009
In the last two months, GenVec Inc. (NASDAQ: GNVC), Human Genome Sciences Inc. (NASDAQ: HGSI), Micromet Inc. (NASDAQ: MITI) and Cytomedix Inc. (AMEX: GTF) have sold stock to raise anywhere from $1. 5 million to $358 million. (Washington Business Journal, DC)
PATIENT'S PLEA: Fight Cancer With Star Power Sep 15, 2009
In the Loughman's case, GenVec, the company testing the cancer drug, denied the Loughman's request. Robert Young, chancellor of Fox Chase Cancer Center in Philadelphia, emphasized why companies don't always give the green light. (ABC News)
GenVec raises $5.6M from investors Aug 28, 2009
GenVec is selling its shares at 75 cents apiece in this transaction, whereas its stock closed at 82 cents on Wednesday. In all, GenVec (NASDAQ: GNVC) expects to bring in $6 million before expenses ... After raising $6 million in gross proceeds in a stock offering in late May, GenVec has announced a series of new recent federal grants and contract extensions that have further pumped up its incoming cash. (Baltimore Business Journal, MD)
Local biotechs search for partners to help them survive Jun 28, 2009
for free extra services. Subscribe to Washington Business Journal. (Washington Business Journal, DC)
GenVec plans to raise $5.5M May 29, 2009
GenVec plans to raise $5 ... GenVec plans to raise $5 ... The deal s share price comes at a 21 percent discount on GenVec s (NASDAQ: GNVC) closing price of 79 cents on Wednesday. (Washington Business Journal, DC)
GenVec narrows 1Q loss May 9, 2009
Last year, GenVec (NASDAQ: GNVC) made $3 ... In January, GenVec laid off 22 people and management said Friday that it didn t receive bonuses last year, also in efforts to cut costs ... In that time, GenVec drew down a total $6. (Washington Business Journal, DC)
Michael Egan, 56, scientist devoted to Boston May 6, 2009
In 2003, Mr. Egan was named senior vice president of commercial development when Diacrin merged with Maryland-based GenVec Inc.. During this time, Mr. Egan moved nine product candidates from research to clinical development, according to a statement announcing his 2005 selection as chief executive officer of TransMolecular Inc., an oncology-focused biotechnology company in Cambridge. (Boston Globe)
Swine flu fear lifts Novavax stock Apr 28, 2009
By Monday afternoon, GenVec Inc. (NASDAQ: GNVC) of Gaithersburg and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) of Rockville watched as their respective shares climbed by 4 cents, or nearly 7 percent, to 68 cents and by 19 cents, or 20 percent, to $1. 13. (Washington Business Journal, DC)
GenVec may end deal with British firm Mar 26, 2009
The companies first entered into their agreement in January 2008 for Cobra to help GenVec scale up its production capacity of TNFerade at its plant in Oxford, England. At the time, GenVec paid a $1 million advance fee to Cobra for a two-year contract whose value could rise as much as $9 ... Last year, GenVec said it paid Cobra $3. (Washington Business Journal, DC)
GenVec lays off 22 people Feb 8, 2009
The move, effective immediately, will lower GenVec s head count to 101 people ... GenVec (NASDAQ: GNVC) will also cut out discretionary spending to focus its attention and dollars on its key product, TNFerade, a pancreatic cancer treatment that s in its third phase of clinical trials ... But the treatment s chances for survival dropped after two years to just above survival chances of the current standard of care news that sent GenVec shares plunging by 43 percent in mid-November. (Washington Business Journal, DC)
